Log in

NASDAQ:TBPH - Theravance Biopharma Stock Price, Forecast & News

$25.08
-0.03 (-0.12 %)
(As of 02/17/2020 04:24 AM ET)
Add
Today's Range
$24.80
Now: $25.08
$25.37
50-Day Range
$23.63
MA: $26.35
$31.21
52-Week Range
$15.18
Now: $25.08
$31.54
Volume262,426 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Theravance Biopharma, Inc, a diversified biopharmaceutical company, discovers, develops, and commercializes organ-selective medicines. The company offers VIBATIV, a bactericidal, once-daily injectable antibiotic to treat patients with serious, life-threatening infections due to staphylococcus aureus and other gram-positive bacteria, including methicillin-resistant. Read More…

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
Current SymbolNASDAQ:TBPH
Previous SymbolNASDAQ:TBPHV
CUSIPN/A
WebN/A
PhoneN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees363
Next Earnings Date2/24/2020 (Confirmed)
OptionableOptionable

Receive TBPH News and Ratings via Email

Sign-up to receive the latest news and ratings for TBPH and its competitors with MarketBeat's FREE daily newsletter.


Theravance Biopharma (NASDAQ:TBPH) Frequently Asked Questions

What is Theravance Biopharma's stock symbol?

Theravance Biopharma trades on the NASDAQ under the ticker symbol "TBPH."

How were Theravance Biopharma's earnings last quarter?

Theravance Biopharma Inc (NASDAQ:TBPH) announced its quarterly earnings results on Tuesday, November, 5th. The biopharmaceutical company reported ($1.05) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($1.05). The biopharmaceutical company had revenue of $12.43 million for the quarter, compared to the consensus estimate of $13.33 million. View Theravance Biopharma's Earnings History.

When is Theravance Biopharma's next earnings date?

Theravance Biopharma is scheduled to release their next quarterly earnings announcement on Monday, February 24th 2020. View Earnings Estimates for Theravance Biopharma.

How can I listen to Theravance Biopharma's earnings call?

Theravance Biopharma will be holding an earnings conference call on Monday, February 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for TBPH?

4 brokers have issued 1-year target prices for Theravance Biopharma's shares. Their forecasts range from $18.00 to $55.00. On average, they anticipate Theravance Biopharma's share price to reach $35.75 in the next year. This suggests a possible upside of 42.5% from the stock's current price. View Analyst Price Targets for Theravance Biopharma.

What is the consensus analysts' recommendation for Theravance Biopharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Theravance Biopharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Theravance Biopharma.

What are Wall Street analysts saying about Theravance Biopharma stock?

Here are some recent quotes from research analysts about Theravance Biopharma stock:
  • 1. Cantor Fitzgerald analysts commented, ". We believe it is a good time to take another look at TBPH given its inexpensive valuation, and ahead of important catalysts this year. We also note that TBPH’s cash and equivalents totaled $517.1MM as of 12/31/18. It appears well-positioned to receive over $1B in milestones and payments, but its market cap is only ~$1.3B. Therefore, we think the peak sales potential of TBPH’s organ-selective Trelegy, are all underappreciated. Our positive investment thesis supports our OW rating and 12-month PT of $55." (4/12/2019)
  • 2. According to Zacks Investment Research, "Theravance reported narrower-than-expected loss in Q4. Also, revenues beat estimates. The company received a huge boost when the FDA approved Yupelri, the first once daily nebulized LAMA option for COPD, in November. Formal launch activities of Yupelri are currently underway. Meanwhile, the agreement to divest its only marketed drug, Vibativ, will enable Theravance to focus solely on the launch efforts of Yupelri. Moreover, its pipeline programs target highly competitive therapeutic areas. The company's collaboration agreements are a consistent source of funds. However, any agreement termination might be a huge setback for the company as was the case in the past. Shares of the company have underperformed the industry so far this year." (3/13/2019)

Has Theravance Biopharma been receiving favorable news coverage?

Media headlines about TBPH stock have been trending somewhat positive recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Theravance Biopharma earned a coverage optimism score of 1.8 on InfoTrie's scale. They also assigned media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Theravance Biopharma.

Are investors shorting Theravance Biopharma?

Theravance Biopharma saw a decrease in short interest during the month of January. As of January 15th, there was short interest totalling 2,640,000 shares, a decrease of 5.4% from the December 31st total of 2,790,000 shares. Based on an average trading volume of 307,900 shares, the days-to-cover ratio is presently 8.6 days. Approximately 6.9% of the company's stock are sold short. View Theravance Biopharma's Current Options Chain.

What other stocks do shareholders of Theravance Biopharma own?

Who are Theravance Biopharma's key executives?

Theravance Biopharma's management team includes the folowing people:
  • Mr. Rick E. Winningham, Chairman & CEO (Age 59)
  • Mr. Bradford J. Shafer, Exec. VP, Gen. Counsel & Sec. (Age 59)
  • Dr. Shehnaaz Suliman M.D., M.Phil., M.B.A., Sr. VP of Corp. Devel. & Strategy (Age 46)
  • Dr. Brett K. Haumann, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 49)
  • Mr. Vijay Sabesan, Sr. VP of Technical Operations

Who are Theravance Biopharma's major shareholders?

Theravance Biopharma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Link Fund Solutions Ltd (9.25%), State Street Corp (1.69%), Chescapmanager LLC (1.67%), Jacobs Levy Equity Management Inc. (0.80%), Candriam Luxembourg S.C.A. (0.49%) and Charles Schwab Investment Management Inc. (0.47%). Company insiders that own Theravance Biopharma stock include Bradford J Shafer, Burton G Malkiel, Donal O'connor, Philip D Worboys, Renee D Gala, Sharathchandra S Hegde and Vijay Sabesan. View Institutional Ownership Trends for Theravance Biopharma.

Which major investors are selling Theravance Biopharma stock?

TBPH stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Citigroup Inc., Virtus ETF Advisers LLC, Bank of America Corp DE, Chicago Equity Partners LLC, New York State Common Retirement Fund, Nisa Investment Advisors LLC and ProShare Advisors LLC. Company insiders that have sold Theravance Biopharma company stock in the last year include Donal O'connor, Sharathchandra S Hegde and Vijay Sabesan. View Insider Buying and Selling for Theravance Biopharma.

Which major investors are buying Theravance Biopharma stock?

TBPH stock was acquired by a variety of institutional investors in the last quarter, including Link Fund Solutions Ltd, Chescapmanager LLC, Laurion Capital Management LP, Jacobs Levy Equity Management Inc., Credit Suisse AG, First Trust Advisors LP, Cubist Systematic Strategies LLC and California Public Employees Retirement System. View Insider Buying and Selling for Theravance Biopharma.

How do I buy shares of Theravance Biopharma?

Shares of TBPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Theravance Biopharma's stock price today?

One share of TBPH stock can currently be purchased for approximately $25.08.


MarketBeat Community Rating for Theravance Biopharma (NASDAQ TBPH)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  274 (Vote Outperform)
Underperform Votes:  306 (Vote Underperform)
Total Votes:  580
MarketBeat's community ratings are surveys of what our community members think about Theravance Biopharma and other stocks. Vote "Outperform" if you believe TBPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TBPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel